| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 7.6 | 12.8 |
| Profit before tax | -16.5 | -15.4 |
| Net income | -16.5 | -15.4 |
| EPS (diluted, $ a share) | $-0.13 | $-0.14 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -41.0% |
|---|---|
| Operating margin | -191.5% |
10-Q filed with the SEC, NASDAQ: AQST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aquestive Therapeutics, Inc.: key numbers
- Share price
- $3.76Close, Nov 16
- Market cap
- $473M
- Shares outstanding
- 125.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aquestive Therapeutics, Inc.
All →Aquestive Therapeutics Investor Presentation
Aquestive Therapeutics filed an investor presentation for the Jefferies Global Healthcare Conference on November 16, 2026. The presentation provides updates on the regulatory status of Anaphylm (epinephrine) sublingual film, including the March 16, 2027 PDUFA goal date, and the commercial launch strategy for the product if approved.
Aquestive Therapeutics Director Richard J. Daly Buys $95.1K of Stock
Richard J. Daly, Director, bought 26,825 shares of Aquestive Therapeutics, Inc. at $3.54 a share, worth $95.1K in total on Nov 10, 2026. Shares held after the trade: 28,025 (+2235.4%).
- Value
- $95.1K
- Shares
- 26,825
- Price
- $3.54
- Role
- Director
- Holding change
- +2235.4%
- Trade date
- Nov 10, 2026
Aquestive Therapeutics Investor Presentation
Aquestive Therapeutics filed a corporate investor presentation for November 2026 to be used in meetings with institutional investors and analysts. The presentation provides updates on the regulatory status of Anaphylm (sublingual epinephrine) following its NDA resubmission, which has a PDUFA goal date of March 16, 2027, and the development of its AdrenaVerse pipeline including AQST-108.
Aquestive Therapeutics Financial Results
Aquestive Therapeutics reported Q3 2026 financial results and provided a regulatory update for its lead candidate Anaphylm, which has a PDUFA goal date of March 16, 2027. The company is preparing for a potential U.S. launch and plans to submit regulatory filings in Canada and the EU in late 2026 and early 2027.
- Term
- Q3 2026
“With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved. For decades, people at risk of anaphylaxis have had limited treatment options. We believe Anaphylm - designed to be easy to carry and use confidently whenever and wherever it may be needed - has the potential to address important unmet needs.”
Daniel Barber, President and Chief Executive Officer of Aquestive
Aquestive Therapeutics President and CEO Daniel Barber Sells $106K of Stock
Daniel Barber, President and CEO, sold 25,000 shares of Aquestive Therapeutics, Inc. at $4.22 a share, worth $106K in total on Oct 15, 2026. Shares held after the trade: 627,317 (-3.8%).
- Value
- $106K
- Shares
- 25,000
- Price
- $4.22
- Role
- President and CEO
- Holding change
- -3.8%
- Trade date
- Oct 15, 2026
Aquestive Therapeutics Business Update
Aquestive Therapeutics announced that the FDA has accepted its NDA resubmission for Anaphylm (dibutepinephrine) sublingual film as complete and assigned a PDUFA goal date of March 16, 2027. The resubmission follows positive results from studies designed to address a prior Complete Response Letter, positioning Anaphylm to potentially become the first oral rescue medication for severe allergic reactions.